Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 4 de 4
Filter
Add more filters










Database
Language
Publication year range
1.
Int Immunopharmacol ; 99: 107929, 2021 Oct.
Article in English | MEDLINE | ID: mdl-34343940

ABSTRACT

OBJECTIVE: To explore the effect of programmed death 1 (PD-1) inhibitor combined with apatinib on immune regulation and efficacy of the combined therapy in mice bearing gastric cancer (MBGC), and to provide a research basis for enhancing the benefit of immunotherapy in advanced gastric cancer (AGC). METHODS: MBGC were divided into normal saline group (group NS), apatinib group (group A), PD-1 inhibitors group (group B) and PD-1 inhibitors combined with apatinib group (group C). Tumor inhibition rates were calculated. Cytokine levels and expression of immune cells and molecules were detected, and the pathological manifestations of tumor tissues were observed. RESULTS: Group C had the smallest tumor volume (115.17 ± 16.08 mm3) with a tumor inhibition rate of 89.4% ± 0.69%, significantly increased levels of CD4+T and CD8+T cells in tumor tissues (P < 0.01), the down-regulated proportion of myeloid-derived suppressor cells (MDSCs) (P < 0.01), and levels of PD-1 of CD8+T cells (PD-1+CD8+T) (P < 0.01). There was no difference in the levels of PD-1+CD8+T, CD4+T cells, and MDSCs between groups B and C. Besides, combination therapy increased the levels of interleukin-2 (IL-2), interferon-gamma (IFN-γ), and tumor necrosis factor-ɑ (TNF-ɑ) in tumor tissue and serum. We also found that the anti-angiogenic effect of apatinib increased programmed death ligand-1 (PD-L1) levels, down-regulated vascular endothelial growth factor receptor 2 (VEGFR-2) levels, and induced an increase in the extent of tumor tissue necrosis. CONCLUSION: PD-1 inhibitors in combination with apatinib may help improve treatment outcomes and increase survival benefits in patients with AGC.


Subject(s)
Antineoplastic Agents/chemistry , Immune Checkpoint Inhibitors/chemistry , Protein Kinase Inhibitors/chemistry , Pyridines/chemistry , Stomach Neoplasms/drug therapy , Tumor Microenvironment/drug effects , Angiogenesis Inhibitors/pharmacology , Animals , Antineoplastic Agents/pharmacology , Combined Modality Therapy , Cytokines/metabolism , Female , Gene Expression Regulation , Humans , Immune Checkpoint Inhibitors/pharmacology , Mice , Myeloid-Derived Suppressor Cells , Protein Kinase Inhibitors/pharmacology , Pyridines/pharmacology , Skin , T-Lymphocytes
2.
J Cancer Res Clin Oncol ; 147(2): 517-531, 2021 Feb.
Article in English | MEDLINE | ID: mdl-33237432

ABSTRACT

OBJECTIVE: V-domain Ig suppressor of T cell activation (VISTA) is a novel immune checkpoint protein that belongs to the B7 family. The aim of this study was to investigate the prognostic significance and therapeutic potential of VISTA in patients with pancreatic cancer. METHODS: Using immunohistochemistry (IHC), we examined the expression of VISTA and demonstrated the associations between the VISTA and overall survival in 223 PDAC patients from 2 different unrelated retrospective cohorts. The multiplex immunofluorescence was performed to illuminate the relationship between VISTA expression and tumor-infiltrating immune cell subclusters of PDAC. We also verified the findings in The Cancer Genome Atlas (TCGA) dataset. The anti-tumor effect of anti-VISTA therapy was studied by the mouse model with liver metastases of PDAC. RESULTS: The VISTA protein was highly expressed in 25.6% of tumor cells (TCs), 38.1% of immune cells, and 26.0% of endothelial cells in 223 PDAC tumor tissues. VISTA expression in TCs was significantly associated with prolonged overall survival. Multiplex immunofluorescence analysis revealed that VISTA level was positively correlated with CD68+ macrophages, CD3+ T cells, and CD19+ B cells in PDAC. However, a higher expression level of VISTA was detected in tumor-infiltrating CD68+ macrophages than in CD3+ T and CD19+ B cells. Furthermore, anti-VISTA antibody treatment significantly reduced the number of metastatic nodules in livers of mouse models of PDAC with liver metastases. CONCLUSION: VISTA expressed in TCs is associated with a favorable prognosis in PDAC. Moreover, immunotherapy with anti-VISTA antibodies may potentially be an effective treatment strategy against PDAC.


Subject(s)
B7 Antigens/analysis , Carcinoma, Pancreatic Ductal/mortality , Immune Checkpoint Inhibitors/therapeutic use , Pancreatic Neoplasms/mortality , B7 Antigens/antagonists & inhibitors , B7-H1 Antigen/analysis , Carcinoma, Pancreatic Ductal/chemistry , Carcinoma, Pancreatic Ductal/immunology , Carcinoma, Pancreatic Ductal/secondary , Cell Line, Tumor , Fluorescent Antibody Technique , Humans , Liver Neoplasms/drug therapy , Liver Neoplasms/secondary , Pancreatic Neoplasms/chemistry , Pancreatic Neoplasms/immunology , Pancreatic Neoplasms/pathology , Prognosis , Tumor Microenvironment
3.
Environ Sci Pollut Res Int ; 28(6): 6990-7000, 2021 Feb.
Article in English | MEDLINE | ID: mdl-33025435

ABSTRACT

Research indicates that air pollution is a risk factor of an increased occurrence of diseases. However, evidence is limited on the effects of the pollution index on disease and whether temperature modifies the effects. The objectives were (i) to explore the effects of the Air Pollution Index (API) and specific indices for pollutants (PM10, NO2, and SO2) on respiratory emergency department (ED) visits in Beijing and (ii) to investigate whether temperature modified the effects of main air pollutants on respiratory ED visits. A quasi-Poisson generalized additive model was employed to examine the association of API and indices for pollutants with respiratory disease. Bivariate response surface model and stratification model (cold days, moderately cold days, moderately hot days, and hot days) were used to analyze the modification effects of temperature on air pollution and respiratory disease. The results showed that (i) the effects of API on respiratory diseases were similar to the index for PM10 in Beijing. (ii) API and PM10 were associated with increased respiratory ED visits on cold days and moderately cold days. Furthermore, the effects of PM10 on respiratory disease on moderately cold days [Relative risk (RR) = 1.006 per 10 µg/m3, 95% CI 1.002-1.009] were stronger than on cold days (RR = 1.004 per 10 µg/m3, 95% CI 1.000-1.008). (iii) PM10 (API) had a greater impact on children aged 10 to 17 years and females on moderately cold days, while the elderly had an increased risk of respiratory disease to PM10 (RR = 1.008 per 10 µg/m3, 95% CI 1.002-1.013) and API (RR = 1.013 per 10, 95% CI 1.004-1.022) on cold days. In conclusion, temperature can modify the association between API and respiratory morbidity. A stronger correlation existed between PM10 and respiratory diseases on moderately cold days, while the effects of cold days were less than that attributable to moderately cold days.


Subject(s)
Air Pollutants , Air Pollution , Adolescent , Aged , Air Pollutants/adverse effects , Air Pollutants/analysis , Air Pollution/adverse effects , Air Pollution/analysis , Beijing , Child , China , Emergency Service, Hospital , Female , Humans , Particulate Matter/adverse effects , Particulate Matter/analysis , Temperature
4.
Cell Death Dis ; 11(7): 589, 2020 07 27.
Article in English | MEDLINE | ID: mdl-32719347

ABSTRACT

Radiofrequency ablation (RFA) is an effective local therapy approach for treating solitary tumor of many types of malignancy. The impact of RFA on the tumor immune microenvironment on distant tumors after RFA treatment is still unclear. In this study, by using syngeneic tumor models and single-cell RNA and T-cell receptor sequencing, we have investigated the alterations of tumor-infiltrating immune cells in distant non-RFA tumors. Single-cell RNA sequencing identified six distinct lymphoid clusters, five distinct monocyte/macrophage clusters, three dendritic cells clusters, and one cluster of neutrophils. We found that RFA treatment reduced the proportions of immunosuppressive cells including regulatory T cells, tumor-associated macrophages and tumor-associated neutrophils, whereas increased the percentages of functional T cells in distant non-RFA tumors. Moreover, RFA treatment also altered gene expressions in single-cell level in each cell cluster. By using pseudo-time analysis, we have described the biological processes of tumor-infiltrating CD8+ T cells and monocytes/macrophages based on the transcriptional profiles. In addition, the immune checkpoints including PD-1 and LAG3 were upregulated in the T cells in distant non-RFA tumors after RFA treatment. In conclusion, our data indicate that RFA treatment induced remodeling of tumor immune microenvironment in distant non-RFA tumors in pancreatic cancer mouse model and suggest that combining RFA with immune checkpoint inhibitors may be an effective treatment approach.


Subject(s)
Pancreatic Neoplasms/immunology , Radiofrequency Ablation , Single-Cell Analysis , Tumor Microenvironment/immunology , Animals , Cell Line, Tumor , Disease Models, Animal , Gene Expression Regulation, Neoplastic , Immunity, Innate , Lymphocytes, Tumor-Infiltrating/immunology , Male , Mice, Inbred C57BL , Pancreatic Neoplasms/genetics , Pancreatic Neoplasms/pathology , Receptors, Antigen, T-Cell/metabolism , T-Lymphocytes, Regulatory/immunology , Pancreatic Neoplasms
SELECTION OF CITATIONS
SEARCH DETAIL
...